“…MCM3AP-AS1 was also found to be upregulated in Burkitt lymphoma, glioblastoma, LC, nasopharyngeal carcinoma, clear cell renal cell carcinoma, pancreatic cancer, and papillary thyroid cancer tissues compared to the corresponding normal tissues (Yang et al, 2017(Yang et al, , 2019Liang et al, 2019;Guo et al, 2020;Li et al, 2020b;Qiu et al, 2020;Sun et al, 2020) In contrast to the above findings, MCM3AP-AS1 expression is markedly downregulated in CSCC tissue samples and predicts a poor outcome. Overexpression of MCM3AP-AS1 reduces CSCC cell proliferation, and MCM3AP-AS1 acts as a tumor suppressor during CSCC development and progression.…”